L.I. Korytova, A.V. Meshechkin, V.G. Krasnikova, O.V. Korytov
Russian Scientific Center of Radiology and Surgical Technologies, Saint Petersburg
Korytova L.I. ― D. Med. Sc., Professor, Deputy Director for Clinical Radiology, Head 2 radiotherapy department of the Russian Scientific Center of Radiology and Surgical Technologies, Honored Worker of Science
70/4 Leningradskaya Str., Pesochnyy settlement, St. Petersburg, Russian Federation, 197758, tel.: (812) 439-66-30, +7-921-553-49-41, e-mail: email@example.com
Main task ― evaluating the effectiveness of sodium nukleospermat for the treatment and prevention of thrombocytopenia with combined chemoradiation therapy of cancer patients.
Methods. The study includes data of 40 patients that underwent combined treatment in the Russian Scientific Center of Radiology and Surgical Technologies from January to December 2016. After developing thrombocytopenia patients were randomized into two groups (20 patients in each): treated group, where patients received sodium nucleospermat, and control group. Thrombocyte level control was done on 5th, 10th and 15th day after treatment was over.
Results. When administered to patients with sodium nukleospermata positive dynamics (+41%) of platelet levels was observed immediately after the completion of dosing in all 20 patients, which was confirmed by the first (5th day) pilot study blood parameters. The average platelet count in patients after treatment of thrombocytopenia Sodium nucleospermat virtually normalized and averaged 172×109/l (+83%). Only the 3rd group of patients took a break from radiation therapy for 5 days. In the group of patients not receiving the drug sodium nukleospermat, the positive dynamics (+12%) of the recovery of platelet levels revealed only to the second (10th day) controlled trials of blood analysis. Thus, increasing the level of platelets was insignificant. The average platelet count among all the patients in the control group was 116×109/l (+19%). Low platelet levels in 13 (65%) of the control group patients required interruption of radiation therapy for 5-10 days.
Conclusion. Sodium nucleospermat had allowed to raise thrombocyte level to the lower normal range, which by 40-50% surpassed patients in control group. Use of sodium nucleospermat did not show any cases of allergic reactions, toxicity or complications in oncological patients. Sodium nucleospermat also affects the white and red sprouts blood, which indicates a positive impact on all the germs of hematopoiesis and can enhance the effectiveness of the treatment of cancer patients without the use of colony-stimulating factors.
Key words: thrombocytopenia, chemoradiotherapy, sodium nucleospermat.